Abstracts tagged "GWAS and scleroderma"

Abstract Number: 2930 • 2017 ACR/ARHP Annual Meeting
Transforming Growth Factor Beta 3 (TGFB3) – a Novel Systemic Sclerosis Susceptibility Locus Involved in Fibrosis and Th17 Cell Development Identified By Genome-Wide Association Study in African Americans from the Genome Research in African American Scleroderma Patients Consortium
Pravitt Gourh¹, Elaine F. Remmers², Ansuman Satpathy³, Steven Boyden⁴, Nadia D. Morgan⁵, Ami A. Shah⁶, Adebowale Adeyemo², Amy Bentley², Mary A. Carns⁷, Settara C Chandrasekharappa², Lorinda Chung⁸, Lindsey A. Criswell⁹, Chris T. Derk¹⁰, Robyn T. Domsic¹¹, Ayo Doumatey², Heather Gladue¹², Avram Goldberg¹³, Jessica K. Gordon¹⁴, Vivien Hsu¹⁵, Reem Jan¹⁶, Dinesh Khanna¹⁷, Maureen D. Mayes¹⁸, Thomas A. Medsger Jr.¹⁹, Maxwell Mumbach³, Paula S. Ramos²⁰, Marcin Trojanowski²¹, Lesley Ann Saketkoo²², Elena Schiopu¹⁷, Victoria K. Shanmugam²³, Daniel Shriner², Richard M. Silver²⁴, Virginia D. Steen²⁵, Antonia Valenzuela²⁶, John Varga²⁷, Howard Chang³, Charles Rotimi², Fredrick M. Wigley²⁸, Francesco Boin²⁹ and Daniel L. Kastner³⁰, ¹NIAMS-Rheumatology, National Institutes of Health (NIH), National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, ²National Institutes of Health (NIH), National Human Genome Research Institute, Bethesda, MD, ³Stanford University, Stanford, CA, ⁴National Institutes of Health (NIH), National Institute on Deafness and Other Communication Disorders, Bethesda, MD, ⁵Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁶Division of Rheumatology, Johns Hopkins University, Baltimore, MD, ⁷Northwestern University, Feinberg School of Medicine Scleroderma Program, Chicago, IL, ⁸Rheumatology, Stanford University Medical Center, Palo Alto, CA, ⁹Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ¹⁰Rheumatology, University of Pennsylvania, Philadelphia, PA, ¹¹Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA, ¹²Rheumatology, Arthritis and Osteoporosis Consultants of the Carolinas, Charlotte, NC, ¹³NYU Langone Medical Center, New York, NY, ¹⁴Rheumatology, Hospital for Special Surgery, New York, NY, ¹⁵Rheumatology, Robert Wood Johnson University Scleroderma Program, New Brunswick, NJ, ¹⁶Medicine, Rheumatology, University of Chicago, Chicago, IL, ¹⁷University of Michigan, Ann Arbor, MI, ¹⁸University of Texas McGovern Medical School, Houston, TX, ¹⁹Medicine/Rheumatology, Univ of Pittsburgh, Pittsburgh, PA, ²⁰Department of Public Health Sciences, Medical University of South Carolina, Charleston, SC, ²¹Boston University, Boston, MA, ²²Tulane, New Orleans, LA, ²³Rheumatology, The George Washington University, Washington, DC, ²⁴Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina, Charleston, SC, ²⁵Rheumatology, MedStar Georgetown University Hospital, Washington, DC, ²⁶Stanford University School of Medicine, Stanford, CA, ²⁷Rheumatology and Dermatology, Northwestern University, Feinberg School of Medicine Scleroderma Program, Chicago, IL, ²⁸Rheum Div/Mason F Lord, Johns Hopkins University, Baltimore, MD, ²⁹Rheumatology, University California, San Francisco, San Francisco, CA, ³⁰Inflammatory Disease Section, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD
Background/Purpose: Systemic sclerosis (SSc) is a multisystem disease that has a higher prevalence in African Americans (AA), with a more severe phenotype, internal organ involvement,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].